# A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

> **NCT05231850** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 70 (estimated)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05231850
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05231850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05231850, "A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05231850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*